SCNI - Scinai Immunotherapeutics Ltd - ADR
IEX Last Trade
3.85
-0.070 -1.818%
Share volume: 9,489
Last Updated: Fri 30 Aug 2024 05:23:40 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.92
-0.07
-1.79%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-7.90%
1 Month
-13.19%
3 Months
3.61%
6 Months
-21.47%
1 Year
178.36%
2 Year
-66.24%
Key data
Stock price
$3.85
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.31 - $13.70
52 WEEK CHANGE
$1.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Ron Babecoff
Region: US
Website: http://www.biondvax.com
Employees: 26
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.biondvax.com
Employees: 26
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. biondvax’s technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.
Recent news